Browsing by Author "Yildirim, Hasan Cagri"
Now showing items 1-7 of 7
-
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ... -
The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Cakir, Ibrahim Yahya; Ucgul, Enes; Yildirim, Hasan Cagri; Aktepe, Oktay Halit; Erman, Mustafa; Kilickap, Saadettin; Aksoy, Sercan; Yalcin, Suayib (MDPI, 2022)Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the ... -
Blood based biomarkers as predictive factors for hyperprogressive disease
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aksoy, Sercan; Erman, Mustafa; Kilickap, Saadettin; Yalcin, Suayib (MDPI, 2022)Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known ... -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan; Yildirim, Hasan Cagri; Tunc, Sezai; Ozyurt, Neslihan; Ozdemir, Feyyaz; Sendur, Mehmet Ali Nahit; Kilickap, Saadettin (LIPPINCOTT WILLIAMS & WILKINS, 2022)Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study -
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
Yildirim, Hasan Cagri; Mutlu, Emel; Chalabiyev, Elvin; Ozen, Mirac; Keskinkilic, Merve (Churchill Livingstone, 2022)Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone ... -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
Guven, Deniz Can; Sahin, Taha Koray; Yildirim, Hasan Cagri; Cesmeci, Engin; Gulbahce Incesu, Fatima Gul; Kilickap, Saadettin (BMJ, 2021)Background: We compared the new outpatient clinic referrals during the first 10 months of the COVID-19 pandemic with the year before. Methods: We compared baseline characteristics of the 2208 new referrals in 2020 (n=922) ...
